Tezepelumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Tezepelumab
Monoclonal antibody
Type Whole antibody
Source Human
Target TSLP
Clinical data
Synonyms MEDI9929, AMG 157
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6400H9844N1732O1992S52
Molar mass 144.6 kDa

Tezepelumab (MEDI9929, AMG 157) (INN) is a human monoclonal antibody designed for the treatment of asthma and atopic dermatitis[1][2]. It blocks Thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation [3].

This drug is being developed in collaboration by MedImmune, LLC and Amgen.

It is currently at Phase III trials.

References[edit]